Titan Spine today touted results from a research review of spinal implant surface technology, including its NanoLock surface tech, touting its ability to improve osteogenic response.
The review was published in the journal Spine, the Mequon, Wisc.-based company said.
The NanoLock surface technology features micro and nano-scaled architecture the company claims can improve osteogenic responses. The technology has received clearance from the FDA and has received a new technology category designation from the Centers for Medicare & Medicaid Services.
The article, written by Titan Spine chief medical officer Dr. Paul Slosar, examines differences between spinal implant surface technologies, how they were manufactured and what materials are used in such implants.
The review reports that the company’s titanium nanotextured surface interacts with cells on a molecular level to generate cellular responses to drive bone production that it claims porous or micron-scale implant surfaces cannot. The article also suggests that the combination of implant material and nano-scale surface is “critical to the ability to stimulate bone formation.”
“There has been a substantial increase in the promotion of surface-enhanced interbody devices over the past few years, most of which are backed by unsubstantiated marketing claims rather than by science. I felt the time was right to review the previously-published studies that point to one irrefutable fact – the only way to communicate to a patient’s cells in a meaningful way to drive bone growth is to combine titanium and the correct nano-architecture that only Titan Spine’s nanoLOCK surface possesses. We are just now starting to produce clinical outcome data to determine if faster patient healing can be tied to the in-vitro findings summarized in this most-recent article. We look forward to publishing the data in the near future,” Dr. Slosar said in a press release.
Last January, Titan Spine said it raised $1.5 million in a new round of equity financing.